Search

Your search keyword '"Cardiovascular agents -- Product introduction"' showing total 52 results
Start Over Descriptor "Cardiovascular agents -- Product introduction"
52 results on '"Cardiovascular agents -- Product introduction"'

1. Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois

Subjects
Cardiovascular agents -- Product introduction, Heart attack, Medical tests, Family medicine, Risk assessment, Hypermarkets -- Product introduction, Superstores -- Product introduction, Business, Business, international
Abstract

CHICAGO -- Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company's clinical blood test, Epi+Gen CHD is now available at Family Medicine [...]

Published
2024

2. Ready-to-Use Formulation of Bivalirudin Injection Now Available

Author

Park, Brian

Subjects
Cardiovascular agents -- Product introduction, Bivalirudin -- Product introduction, Cardiac patients -- Drug therapy, Medical care -- Quality management, Thrombin -- Product introduction, Health
Abstract

Endo International has announced the launch of Bivalirudin Injection in a ready-to-use 250mg/50mL single-use vial. Bivalirudin is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing [...]

Published
2023

3. Cardio Diagnostics Holdings, Inc Democratizes CHD Detection with Nationwide Launch of PrecisionCHD[TM]

Subjects
Coronary heart disease, Cardiovascular agents -- Product introduction, Epigenetic inheritance, Democratization, Business, Business, international
Abstract

Coronary Heart Disease Detection Test Merges Epigenetic and Genetic Biomarkers with Artificial Intelligence, Offering Remote and Scalable Deployment Capabilities Across the Nation CHICAGO -- Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), [...]

Published
2023

4. A Pharma Company Developed an Optimal Launch Plan for its New Injectable Cholesterol Drug Using Go-to-Market Strategy | RFP for More Insights

Subjects
Anticholesteremic agents -- Product introduction, Cholesterol, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Business, international
Abstract

LONDON -- Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest go-to-market strategy engagement for a pharma company. This success story pinpoints the [...]

Published
2020

5. Cumberland announces U.S. launch of Totect

Subjects
Cumberland Pharmaceuticals Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, News, opinion and commentary, Totect (Medication) -- Product introduction
Abstract

Cumberland Pharmaceuticals announced the promotional launch of Totect in the U.S. In preparation for the Totect launch, Cumberland has completed the training of its sales and medical organization, stocked the [...]

Published
2017

6. Plavix

Subjects
Bristol-Myers Squibb Co. -- Product introduction, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Arts, visual and performing, General interest, Plavix (Medication) -- Product introduction
Abstract

Plavix, a product of the Bristol Myers Squibb Company is used to prevent heart attacks, or strokes in the future, for the people who are suffering from the heart related chest pain called acquired coronary syndrome. The dosage and the administration details of the drug are mentioned.

Published
2005

7. Plavix

Subjects
Bristol-Myers Squibb Co. -- Product introduction, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Arts, visual and performing, General interest, Plavix (Medication) -- Product introduction
Abstract

Plavix, a product of the Bristol Myers Squibb Company is used to prevent heart attacks, or strokes in the future, for the people who are suffering from the heart related chest pain called acquired coronary syndrome. The dosage and the administration details of the drug are mentioned.

Published
2005

8. The newest critical care drugs, part 1

Author

Chase, Sandra L.

Subjects
Cardiovascular diseases -- Drug therapy, Cardiovascular agents -- Product introduction, Health
Abstract

Developments in pharmacology and biotechnology have led to the formulation of new medications for critical cardiovascular diseases. These medications include class III antiarrhythmic drug called Ibutilide (Corvert), the antihypertensive drug called fenodldopam (Corlopaman) and clopidogrel (Plavix), an antiplatelet agent. The anticoagulant drug, lepirudin (Refludan) and anti heparin-induced thrombocytopenia drug, reteplase (Retavase), are also included., Part One This month we focus our in-depth drug update on meds used in critical care. Here we look at six cardiovascular drugs: ibutilide, fenoldopam, clopidogrel, lepirudin, enoxaparin, and reteplase. [...]

Published
1999

9. Global Cardiovascular Drugs Markets to 2022: Novel Product Launches, Recent Approvals, Research and Development Pipeline, and Blockbuster Drugs

Subjects
Industrial research, Epidemiology, Cardiovascular agents -- Product introduction, Cardiovascular diseases -- Drug therapy, Research and development, Business, Business, international
Abstract

M2 PRESSWIRE-March 21, 2018-: Global Cardiovascular Drugs Markets to 2022: Novel Product Launches, Recent Approvals, Research and Development Pipeline, and Blockbuster Drugs (C)1994-2018 M2 COMMUNICATIONS RDATE:21032018 The 'Cardiovascular Drugs: Global [...]

Published
2018

10. Why you should care about the drugs your doctor prescribes

Subjects
Cardiovascular agents -- Product introduction, Economics
Abstract

Byline: Tracy Weber And Charles Ornstein (ProPublica) Patients currently have to rely on trust that their doctors prescribe them the right drugs. ProPublica's new tool, Prescriber Check-up, for the first [...]

Published
2013

11. Forest Labs Faces Loss of Cash-Cow Drug

Author

Brown, Greg

Subjects
Standard & Poor's Corp. -- Product introduction, Cardiovascular agents -- Product introduction, Computer services industry -- Product introduction, Cattle -- Product introduction, Computer services industry, News, opinion and commentary, Lexapro (Medication) -- Product introduction, Namenda (Medication) -- Product introduction
Abstract

Byline: Greg Brown Forest Labs (FRX) is an interesting niche pharma stock with a strong drug pipeline. However, a cash-cow drug is leaving the fold for generic production, creating a [...]

Published
2012

12. PRODUCTS & PROMOTIONS: FOAM CHARACTERS ... NEIGHBORLY SONGS ... HEART HEALTH

Subjects
QVC UK -- Services, EndoMatrix Inc. -- Product introduction, Songs from the Neighborhood: The Music of Mister Rogers (Video recording), Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Cable television broadcasting industry -- Services, Specialty stores -- Licensing agreements, Company licensing agreement, Business, Food and beverage industries, Retail industry
Abstract

FOAM CHARACTERS CLEVELAND -- Foamies, specialty products for crafters from Darice here, will feature a new licensing agreement this fall featuring Disney's top-selling character brands, including Winnie the Pooh, Disney [...]

Published
2005

13. Servier adds Coversyl 8mg

Subjects
Servier Laboratories Ltd. -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Chemicals, plastics and rubber industries, Pharmaceuticals and cosmetics industries, Coversyl (Medication) -- Product introduction
Abstract

Servier Laboratories will launch Coversyl (perindopril) 8mg tablets next week. The tablets are indicated for all grades of essential and renovascular hypertension, and for congestive and severe heart failure. Price: [...]

Published
2002

14. NESIRITIDE

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, Scios Inc. -- Product introduction -- Laws, regulations and rules, Cardiovascular agents -- Product introduction, Drugs -- Product introduction, Pharmaceutical industry -- Product introduction, Government regulation, Business, Chemicals, plastics and rubber industries
Abstract

The Cardiovascular and Renal Drugs Advisory Committee to the FDA has recommended approval of Scios Inc.'s Natrecor (nesiritide) for the treatment of acute congestive heart [...]

Published
2001

15. Altace gets expanded indication

Subjects
King Pharmaceuticals Inc. -- Product introduction, Wyeth-Ayerst Laboratories -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Retail industry, Altace (Medication) -- Product introduction
Abstract

Altace (ramipril) is now approved to reduce risk of stroke, heart attack and death from cardiovascular causes. Altace is marketed jointly by Wyeth-Ayerst Laboratories and King Pharmaceuticals. Dosage is a [...]

Published
2000

16. FDA approves several Mylan generics

Subjects
Merck & Company Inc. -- Laws, regulations and rules -- Product introduction, Mylan L.L.C. -- Product introduction -- Laws, regulations and rules, Mylan Inc. -- Laws, regulations and rules -- Product introduction, Cardiovascular agents -- Product introduction, Bronchodilator agents -- Laws, regulations and rules, Menopause -- Product introduction, Hormones -- Laws, regulations and rules, Antipsychotic drugs -- Laws, regulations and rules, Pharmaceutical industry -- Laws, regulations and rules -- Product introduction, Government regulation, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

Mylan Laboratories has received Food and Drug Administration approval to manufacture and market Clozapine Tablets in 25 mg and 100 mg strengths. Clozapine is the generic version of Clozaril(R), a [...]

Published
1999

17. From antivirals to Viagra: drug review of '98

Subjects
Pharmaceutical industry -- Product introduction, Antiviral agents -- Product introduction, Antibacterial agents -- Product introduction, Cardiovascular agents -- Product introduction, Business, Business, international, Chemicals, plastics and rubber industries, Engineering and manufacturing industries
Published
1999

18. Medtronic wins FDA nod, CE mark for angioplasty balloon

Author

Garde, Damian

Subjects
Cardiovascular agents -- Product introduction, Angioplasty, Science and technology
Abstract

Byline: Damian Garde Medtronic (http://www.fiercemedicaldevices.com/tags/medtronic ) is expanding its presence in http://www.fiercemedicaldevices.com/tags/peripheral-artery-disease , winning FDA clearance and a CE mark for the Pacific Plus balloon catheter, a next-generation vascular treatment. [...]

Published
2013

20. New products in 1994

Author

Hughes, Susan

Subjects
Genentech Inc. -- Product introduction, Roche Holding Ltd. -- Product introduction, Pfizer Inc. -- Product introduction, Upjohn Co. -- Product introduction, Hoechst AG -- Product introduction, Cystic fibrosis -- Drug therapy, Rheumatoid arthritis -- Drug therapy, Subarachnoid hemorrhage -- Drug therapy, Antidepressants -- Product introduction, Alzheimer's disease -- Drug therapy, Antiviral agents -- Product introduction, Immunosuppressive agents -- Product introduction, Antineoplastic agents -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Pulmozyme (Medication) -- Product introduction, Tenidap (Medication) -- Product introduction, Freedox (Medication) -- Product introduction, Velnacrine (Medication) -- Product introduction
Published
1994

21. The new Merck

Author

Jarvis, Lisa

Subjects
Merck & Company Inc. -- Mergers, acquisitions and divestments, Merck & Company Inc. -- Product introduction, Schering-Plough Corp. -- Mergers, acquisitions and divestments, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Product introduction, Company acquisition/merger, Chemicals, plastics and rubber industries, Engineering and manufacturing industries
Abstract

Pharmaceutical firm Merck & Co. launched a cardiovascular drug pipeline during its R&D day in May 2010. The unveiling of the said pipeline is a follow-up to Merck's acquisition of Schering-Plough. How Merck's managers integrated projects from Merck and from Schering-Plough is also discussed.

Published
2010

22. Drugmaker targets African-American market

Author

Ginsberg, Thomas

Subjects
Bidil (Medication) -- Product introduction, Pharmaceutical industry -- African American market, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, NitroMed Inc. -- African American market, NitroMed Inc. -- Product introduction
Abstract

Byline: Thomas Ginsberg PHILADELPHIA _ Big cities with large black populations quietly became the launchpad this month for a product at the cutting edge of American health care, commerce and […]

Published
2005

23. Supplement with a heart

Author

Johnsen, Michael

Subjects
Bayer AG -- Product introduction, Cardiovascular agents -- Product introduction, Holding companies -- Product introduction, Dietary supplements -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

MORRIST0WN, N.J. -- With the launch of Bayer Aspirin with Heart Advantage, a product that combines the benefits of a low-dose daily regimen of 81 mg aspirin with natural supplement [...]

Published
2008

24. Folmor

Subjects
Folmor (Medication) -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction
Abstract

TRx Pharma, Research Triangle Park, N.C., (919) 313-3560, is introducing Folmor (folic acid 2.5 mg, [B.sub.6] 25 mg, [B.sub.12] 2 mg, and primorine 875 mg). With too much homocysteine as [...]

Published
2007

25. Ranexa

Subjects
CV Therapeutics Inc. -- Product introduction, Biological products industry -- Product introduction, Cardiovascular agents -- Product introduction, Angina pectoris -- Drug therapy, Health, Ranexa (Medication) -- Product introduction
Abstract

Company: CV Therapeutics Rx Pharmacologic class: Antianginal Active ingredient: Ranolazine 500mg; extrel tabs. Indication: Chronic angina that is inadequately controlled with other antianginals; use with amlodipine, β-blockers, or nitrates. Pharmacology: [...]

Published
2006

26. Clopidogrel and silodosin set for Japanese launch

Subjects
Kissei Pharmaceutical Company Ltd. -- Product introduction, Sanofi-Aventis S.A. -- Product introduction, Pharmaceutical industry -- Product introduction, Adrenergic alpha blockers -- Product introduction, Cardiovascular agents -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Plavix (Medication) -- Product introduction, Urief (Medication) -- Product introduction
Published
2006

27. Ranexa

Subjects
CV Therapeutics Inc. -- Product introduction, Angina pectoris -- Drug therapy, Biological products industry -- Product introduction, Cardiovascular agents -- Product introduction
Abstract

Company: CV Therapeutics Rx Pharmacologic class: Antianginal Active ingredient: Ranolazine 500mg: extrel tabs. Indication: Chronic angina that is inadequately controlled with other antianginals; use with amlodipine, [beta]-blockers, or nitrates. Pharmacology: [...]

Published
2006

28. BiDil launched at price premium

Subjects
NitroMed Inc. -- Product introduction, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Cardiovascular agents -- Prices and rates, Company pricing policy, Business, Pharmaceuticals and cosmetics industries, Bidil (Medication) -- Prices and rates, Bidil (Medication) -- Product introduction
Abstract

The reasons behind introduction of NitroMed Inc.'s BiDil at a higher price are examined.

Published
2005

29. Cardiovascular & diabetes protection

Subjects
Enzymotec -- Product development, Pharmaceutical industry -- Product development, Cardiovascular diseases -- Care and treatment, Cardiovascular agents -- Product introduction
Abstract

Enzymotec recently developed a product line marketed under the brand carDiabeat, which is designed to fight the major risks for cardiovascular disorders of diabetes patients. carDiabeat is meant to help [...]

Published
2004

30. Arterial thrombosis - roxifiban acetate. (Therapeutics)

Subjects
Bristol-Myers Squibb Co. -- Product introduction, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Business, Business, international, Chemicals, plastics and rubber industries, Engineering and manufacturing industries, Roxifiban (Medication) -- Product introduction
Published
2002

31. Sanofi's Arixtra Approved. (Markets: Life Sciences)

Subjects
Sanofi Synthelabo Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Chemicals, plastics and rubber industries, Arixtra (Medication) -- Product introduction
Abstract

SANOFI-SYNTHELABO Inc. has received Food & Drug Administration (FDA) approval for its antithrombosis drug Aixtra (fondaparinux sodium). The drug, which is being codeveloped with Akzo Nobel's Organon, will compete with [...]

Published
2001

32. CV Therapeutics Announces Completion of Phase II Clinical Study of CVT-124 in Congestive Heart Failure

Subjects
CV Therapeutics Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Diuretics -- Product introduction, Business, News, opinion and commentary
Abstract

PALO ALTO, Calif., Oct. 29 /PRNewswire/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced results of a Phase II clinical study of CVT-124, a potent adenosine A1 receptor antagonist being [...]

Published
1997

33. Sherwood-Davis & Geck Announces New Approval For Early Ambulation For Angio-Seal(TM) Device

Subjects
Sherwood-Davis and Geck -- Product introduction, Cardiovascular agents -- Product introduction, Medical test kit industry -- Product introduction, Medical equipment and supplies industry -- Product introduction, Business, News, opinion and commentary
Abstract

ST. LOUIS, Oct. 2 /PRNewswire/ -- Sherwood-Davis & Geck, a subsidiary of American Home Products Corporation (NYSE: AHP), has announced the recent approval of an early ambulation (walking) claim for [...]

Published
1997

34. Cardizem(R) Monovial(R) Receives FDA Marketing Approval

Subjects
Hoechst Marion Roussel AG -- Product introduction, Cardiovascular agents -- Product introduction, Drugs -- Vehicles, Drug delivery systems -- Product introduction, Pharmaceutical industry -- Product introduction, Business, News, opinion and commentary
Abstract

KANSAS CITY, Mo., Sept. 16 /PRNewswire/ -- Hoechst Marion Roussel announced today that Cardizem(R) (diltiazem HCl for injection) Monovial(R) has been cleared for use in the United States by the [...]

Published
1997

35. Rules-Based Medicine Introduces CardiovascularMAP™ Multiplex Biomarker Panel to Aid CVD Drug Development

Subjects
Cardiovascular agents -- Product introduction, Cardiovascular diseases -- Drug therapy, Medical research, Medicine, Experimental, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

Rules-Based Medicine (RBM), a leading multiplexed biomarker testing laboratory, announced the launch of CardiovascularMAP, a research tool designed specifically to advance drug development aimed at the treatment of cardiovascular disease [...]

Published
2009

36. Despite Patent Expiries of Leading Therapies, New Product Launches Will Drive a $4.6 Billion Increase in the Coronary Heart Disease Market

Subjects
Pharmaceutical industry -- Intellectual property, Pharmaceutical industry -- Product introduction, Pharmaceutical industry -- Reports, Cardiovascular agents -- Product introduction, Cardiovascular agents -- Reports, Patents -- Reports, Coronary heart disease -- Reports, Patent/copyright issue, Biotechnology industry, Business
Abstract

Decision Resources (Waltham, MA), one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite the patent expiries by 2012 of the two sales-leading [...]

Published
2009

37. FIRST DRUG TREATMENT FOR RAPID CONVERSION OF ATRIAL FIBRILLATION AND FLUTTER NOW AVAILABLE

Subjects
Pharmacia & Upjohn Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, News, opinion and commentary
Abstract

Corvert Injection provides pharmacologic alternative to electrical cardioversion KALAMAZOO, Mich., April 16 /PRNewswire/ -- Pharmacia & Upjohn (NYSE: PNU) today announced that Corvert(TM) Injection (ibutilide fumarate injection), the first drug [...]

Published
1996

38. CARDIZEM(R) LYO-JECT(TM), ADVANCED DELIVERY SYSTEM FOR HEART RATE CONTROL, RELEASED FOR U.S. MARKET

Subjects
Hoechst Marion Roussel Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Drug delivery devices -- Product introduction, Pharmaceutical industry -- Product introduction, Business, News, opinion and commentary
Abstract

KANSAS CITY, Mo., March 25 /PRNewswire/ -- Hoechst Marion Roussel announced the U.S. market release of Cardizem(R) (diltiazem HCI) Lyo- Ject(TM), an advanced delivery system for Cardizem(R) (diltiazem HCI) Injectable, [...]

Published
1996

39. C O R R E C T I O N -- ASTRA MERCK /(Correction Notice)

Subjects
Astra Merck Inc. -- Product introduction, Cardiovascular agents -- Product introduction, Drugs -- Product introduction, Pharmaceutical industry -- Product introduction, Business, News, opinion and commentary
Abstract

In NY055, Prilosec Now Available to Treat Erosive Esophagitis Long Term, moved earlier today, we are advised by a representative of Astra Merck that the there are several changes in [...]

Published
1995

40. Bionutrics targets cardiovascular health

Subjects
Bionutrics Inc. -- Product introduction, Pharmaceutical industry -- Product introduction, Dietary supplements -- Product introduction, Cardiovascular agents -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Retail industry
Abstract

PHOENIX, Ariz. - A new natural cardiovascular dietary supplement that can reportedly lower cholesterol and promote healthy circulation has been launched by Bionutrics Health Products Inc., and its maker expects [...]

Published
1997

41. LEDERLE AND P&G TO CO-PROMOTE ZIAC, FIRST ANTIHYPERTENSIVE DEVELOPED SPECIFICALLY TO ADDRESS DOSE-RELATED SIDE EFFECTS

Subjects
American Cyanamid Co. Lederle Laboratories Div. -- Product introduction -- Marketing -- Contracts, Procter & Gamble Pharmaceuticals -- Contracts -- Product introduction -- Marketing, Cardiovascular agents -- Product introduction, Drugs -- Product introduction, Hypotension -- Product introduction, Antihypertensive drugs -- Marketing, Pharmaceutical industry -- Contracts -- Product introduction, Company marketing practices, Contract agreement, Business, News, opinion and commentary
Abstract

WAYNE, N.J., and CINCINNATI, Nov. 22 /PRNewswire/ -- Lederle Laboratories, a division of American Cyanamid Company (NYSE: ACY), and Procter & Gamble Pharmaceuticals (NYSE: PG) today announced a major agreement [...]

Published
1993

42. Medical device company completes launch of TAXUS Liberte

Subjects
Boston Scientific Corp. -- Product introduction, Cardiovascular agents -- Product introduction, Stent (Surgery) -- Product introduction, Medical test kit industry -- Product introduction, Medical equipment and supplies industry -- Product introduction, Health, Science and technology, Product introduction
Abstract

Boston Scientific Corporation (NYSE:BSX) announced that it has completed the initial launch of its TAXUS Liberte paclitaxel-eluting coronary stent system. The company recently announced that it had launched the next-generation [...]

Published
2005

43. Medical device company completes launch of TAXUS Liberte

Subjects
Boston Scientific Corp. -- Product introduction, Cardiovascular agents -- Product introduction, Stent (Surgery) -- Product introduction, Medical test kit industry -- Product introduction, Medical equipment and supplies industry -- Product introduction, Health, Product introduction
Abstract

Boston Scientific Corporation (NYSE:BSX) announced that it has completed the initial launch of its TAXUS Liberte paclitaxel-eluting coronary stent system. The company recently announced that it had launched the next-generation [...]

Published
2005

44. Medical device company completes launch of TAXUS Liberte

Subjects
Boston Scientific Corp. -- Product introduction, Product introduction, Stents -- Product introduction, Medical equipment industry -- Product introduction, Cardiovascular agents -- Product introduction, Stent (Surgery) -- Product introduction, Medical test kit industry -- Product introduction, Medical equipment and supplies industry -- Product introduction
Abstract

Boston Scientific Corporation (NYSE:BSX) announced that it has completed the initial launch of its TAXUS Liberte paclitaxel-eluting coronary stent system. The company recently announced that it had launched the next-generation [...]

Published
2005

45. One 'breakthrough' in Canada in 1995

Subjects
Pharmacia Inc. -- Product introduction -- 00079997, Upjohn Co. -- Product introduction -- 00309033, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Zinecard (Medication) -- Product introduction
Published
1996

46. Pfizer back on buying spree with $1.3 billion cash bid for Esperion

Subjects
Pfizer Inc. -- Mergers, acquisitions and divestments -- Product introduction, Esperion Therapeutics Inc. -- Mergers, acquisitions and divestments -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Mergers, acquisitions and divestments -- Product introduction, Company acquisition/merger, Pharmaceuticals and cosmetics industries
Abstract

Already the world's largest pharmaceutical firm, Pfizer is planning to increase its strength in the biotechnology sector through an agreed cash offer of $1.3 billion for US company Esperion Therapeutics. [...]

Published
2004

47. Bayer delays launch of Vardenafil impotence drug

Subjects
Bayer AG -- Product introduction, Cardiovascular agents -- Product introduction, Impotence -- Drug therapy, Drugs -- Product introduction, Product safety, Pharmaceutical industry -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Business, international, Levitra (Medication) -- Product introduction
Abstract

M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceuticals and chemicals group Bayer AG has reportedly pushed back the launch of Vardenafil, its rival to Pfizer's impotence drug Viagra. Vardenafil will not [...]

Published
2002

48. E Merck's cardiovascular focus

Subjects
E. Merck -- Product introduction, Pharmaceutical industry -- Product introduction, Cardiovascular agents -- Product introduction, Business, Pharmaceuticals and cosmetics industries
Published
1993

49. Norsk Hydro's cardiac drug approved in five European countries

Subjects
Pronova A/S -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Pharmaceuticals and cosmetics industries, Business, international, Omacor (Medication) -- Product introduction
Abstract

M2 EUROPHARMA-(C)1999-2001 M2 COMMUNICATIONS LTD The health authorities in Britain, Germany, France, Austria and Greece have approved the use of Omacor, a drug developed by the Pronova subsidiary of the [...]

Published
2001

50. ICI's branded generic atenolol in US

Subjects
ICI Pharmaceuticals -- Product introduction, Hanson PLC -- Mergers, acquisitions and divestments, Atenolol -- Product introduction, Cardiovascular agents -- Product introduction, Pharmaceutical industry -- Product introduction, Business, Pharmaceuticals and cosmetics industries
Published
1991

Catalog

Books, media, physical & digital resources
See catalog results